Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAF ^V600 -mutant resectable melanoma: the randomized phase 2 NeoTrio trial.

Autor: Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au.; Royal North Shore Hospital, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au.; Mater Hospital, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia. georgina.long@sydney.edu.au., Carlino MS; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Westmead Hospital, Westmead, New South Wales, Australia.; Blacktown Hospital, Blacktown, New South Wales, Australia., Au-Yeung G; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore Hospital, Sydney, New South Wales, Australia.; Mater Hospital, Sydney, New South Wales, Australia., Shannon KF; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.; Concord Repatriation Hospital, Concord, New South Wales, Australia., Gyorki DE; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Hsiao E; Royal North Shore Hospital, Sydney, New South Wales, Australia., Kapoor R; Mater Hospital, Sydney, New South Wales, Australia.; I-MED Radiology Network, Mater Hospital, Sydney, New South Wales, Australia., Thompson JR; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Batula I; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Howle J; Westmead Hospital, Westmead, New South Wales, Australia., Ch'ng S; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; Chris O'Brien Lifehouse, Sydney, New South Wales, Australia., Gonzalez M; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia., Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Pennington TE; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Mater Hospital, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia., Lo SN; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.; Chris O'Brien Lifehouse, Sydney, New South Wales, Australia.; NSW Health Pathology, Sydney, New South Wales, Australia., Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Royal North Shore Hospital, Sydney, New South Wales, Australia.; Mater Hospital, Sydney, New South Wales, Australia.

Publikováno v: Nature medicine [Nat Med] 2024 Sep; Vol. 30 (9), pp. 2540-2548. Date of Electronic Publication: 2024 Jun 21.